Developing new dosage forms typically requires significant investment in specialized equipment and facilities. Within the WYB GMP Enablement Platform, participants gain access to a broad range of production capabilities without the need to build independent infrastructure.
The platform provides access to:
- Manufacturing capabilities covering up to 46 dosage forms
- Specialized production facilities
- Flexible opportunities for product diversification
- Scalable production capacity across dosage formats
This enables brands to innovate more efficiently and expand their product portfolios with greater flexibility.
